We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Date
- 2025 (20)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (22)
- 2016 (24)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (15)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (12)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (6)
- 1991 (20)
Sponsor content
690 result(s) found, displaying 31 to 40
-
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Australian public assessment report (AusPar)Xenpozyme (olipudase alfa) was approved as an enzyme replacement therapy for the treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency in paediatric and adult patients with Niemann-Pick disease (types A/B or B).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEYFORTUS nirsevimab 50mg in 0.5mL solution for injection prefilled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BEYFORTUS nirsevimab 100mg in 1mL solution for injection prefilled syringe.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd